Background: Data have shown that early initiation of combination antiretroviral treatment (cART) in infants contributes to improved survival and neurodevelopmental, immunologic and growth outcomes. While cART cannot eradicate HIV infection in the majority of perinatally infected infants because of the long half-life of latently infected CD4 cells, time to achievement of viral suppression has been shown to correlate with the size of this resting CD4+ T cell reservoir in early-treated infants. The “Mississippi baby” has raised the possibility that neonatal cART may augment HIV-specific immune responses and block HIV persistence in acute infection, eventually leading to long-term control of HIV in the absence of therapy. This approach would require widespread availability of accurate neonatal diagnostic testing with rapid turnaround time and parental acceptance of aggressive antiretroviral therapy for high-risk infants. The choices for cART in the neonatal age group are limited by the lack of infant formulations and neonatal pharmacokinetic data for many antiretrovirals, as well as concerns about toxicity and efficacy. Conclusions: The promise and challenges of early initiation of cART for high-risk infants will be discussed, but more data on pharmacokinetics, toxicity and efficacy of this approach are needed; if instituted, should be performed in a closely monitored setting, optimally within the context of a research study. At this time, empiric treatment interruption cannot be recommended until the durability of the approach in the Mississippi baby can be confirmed and the findings replicated in other children.